DANNY LY

HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 1483, S.1584 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers

HR 1483, S.1584 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer

HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers

HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements S. 23, HR 1249 (America Invents Act) - legislative proposals regarding patent reform including "first to file" and "supplemental re-examination" issues. Discussions regarding global/free trade agreements and protection of intellectual property

HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Issues related to US position on intellectual property protections offered by US in international trade treaty

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting Discussions regarding clinical trial issues HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including the Independent Payment Advisory Board HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics

HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements S. 23, HR 1249 (America Invents Act) - legislative proposals regarding patent reform including "first to file" and "supplemental re-examination" issues. Discussions regarding global/free trade agreements and protection of intellectual property

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting Discussions regarding clinical trial issues HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including the Independent Payment Advisory Board HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics

HR 5 (Help Efficient, Accessible, Low-cost Timely Healthcare Act of 2011) - issues related medical malpractice reform HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to development of antibiotics

HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Issues related to US position on intellectual property protections offered by US in international trade treaty

S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements S. 23, HR 1249 (America Invents Act) - legislative proposals regarding patent reform including "first to file" and "supplemental re-examination" issues HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issuess related to the development of antibiotics Participate in executive branch discussions regarding intellectual property issues arising in foreign countries Discussions regarding global/free trade agreements and protection of intellectual property

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 5 (Help Efficient, Accessible, Low-cost Timely Healthcare Act of 2011) - issues related medical malpractice reform HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to development of antibiotics

S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements S. 23, HR 1249 (America Invents Act) - legislative proposals regarding patent reform including "first to file" and "supplemental re-examination" issues HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issuess related to the development of antibiotics Participate in executive branch discussions regarding intellectual property issues arising in foreign countries Discussions regarding global/free trade agreements and protection of intellectual property

HR 5 (Help Efficient, Accessible, Low-cost Timely Healthcare Act of 2011) - issues related medical malpractice reform HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to development of antibiotics

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Issues related to US position on intellectual property protections offered by US in international trade treaty

HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research

FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) V (no bill number yet) HR 2112, HR 2190, S1206 - Proposed legisalation regarding FDA appropriations

FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) V (no bill number yet) HR 2112, HR 2190, S1206 - Proposed legisalation regarding FDA appropriations

HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program

HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research

FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) V (no bill number yet) HR 2112, HR 2190, S1206 - Proposed legisalation regarding FDA appropriations

HR 2112, HR 2190, S1206 - Proposed legislation regarding FDA appropriations FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet)

HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program

HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program

HR 2112, HR 2190, S1206 - Proposed legislation regarding FDA appropriations FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet)

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting Discussions regarding clinical trial issues HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including the Independent Payment Advisory Board HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics

HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 1483, S.1584 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting Discussions regarding clinical trial issues HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including the Independent Payment Advisory Board HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers

HR 1483, S.1584 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting Discussions regarding clinical trial issues HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including the Independent Payment Advisory Board HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting Discussions regarding clinical trial issues HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including the Independent Payment Advisory Board HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 1483, S.1584 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer

HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting Discussions regarding clinical trial issues HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including the Independent Payment Advisory Board HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting Discussions regarding clinical trial issues HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including the Independent Payment Advisory Board HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics

HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 1483, S.1584 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program

HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program

HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program

HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program

HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research

HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including the newly-created Independent Payment Advisory Board Monitoring and discussing issues under discussion by the President's Deficit Commission, including recommendations regarding the Independent Payment Advisory Board and Medicare Part D rebates (unassigned) HR 6331 - issues related to legislation regarding development of antibiotics HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including transparency ("Sunshine") reporting requirements 340B Drug Pricing program issues, including expansion of eligible entities and impacts of health care reform changes

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting Discussions regarding clinical trial issues HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including the Independent Payment Advisory Board HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics

HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting Discussions regarding clinical trial issues HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including the Independent Payment Advisory Board HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics

HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicare Part D Coverage Gap Program HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization Issues related to identification and correction of medical edit codes

HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including the newly-created Independent Payment Advisory Board Monitoring and discussing issues under discussion by the President's Deficit Commission, including recommendations regarding the Independent Payment Advisory Board and Medicare Part D rebates (unassigned) HR 6331 - issues related to legislation regarding development of antibiotics HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including transparency ("Sunshine") reporting requirements 340B Drug Pricing program issues, including expansion of eligible entities and impacts of health care reform changes

HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research

HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicare Part D Coverage Gap Program HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization Issues related to identification and correction of medical edit codes

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including the newly-created Independent Payment Advisory Board Monitoring and discussing issues under discussion by the President's Deficit Commission, including recommendations regarding the Independent Payment Advisory Board and Medicare Part D rebates (unassigned) HR 6331 - issues related to legislation regarding development of antibiotics HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including transparency ("Sunshine") reporting requirements 340B Drug Pricing program issues, including expansion of eligible entities and impacts of health care reform changes

HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including the newly-created Independent Payment Advisory Board Monitoring and discussing issues under discussion by the President's Deficit Commission, including recommendations regarding the Independent Payment Advisory Board and Medicare Part D rebates (unassigned) HR 6331 - issues related to legislation regarding development of antibiotics HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including transparency ("Sunshine") reporting requirements 340B Drug Pricing program issues, including expansion of eligible entities and impacts of health care reform changes

HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicare Part D Coverage Gap Program HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization Issues related to identification and correction of medical edit codes

HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicare Part D Coverage Gap Program HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization Issues related to identification and correction of medical edit codes

HR 6331 - patent issues associated with anti-biotics S. 3677, HR 4899 - legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Participate in executive branch discussions regarding intellectual property issues arising in foreign countries

HR 6331 - patent issues associated with anti-biotics S. 3677, HR 4899 - legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Participate in executive branch discussions regarding intellectual property issues arising in foreign countries

HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including the newly-created Independent Payment Advisory Board Monitoring and discussing issues under discussion by the President's Deficit Commission, including recommendations regarding the Independent Payment Advisory Board and Medicare Part D rebates (unassigned) HR 6331 - issues related to legislation regarding development of antibiotics HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including transparency ("Sunshine") reporting requirements 340B Drug Pricing program issues, including expansion of eligible entities and impacts of health care reform changes

HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including the newly-created Independent Payment Advisory Board Monitoring and discussing issues under discussion by the President's Deficit Commission, including recommendations regarding the Independent Payment Advisory Board and Medicare Part D rebates (unassigned) HR 6331 - issues related to legislation regarding development of antibiotics HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including transparency ("Sunshine") reporting requirements 340B Drug Pricing program issues, including expansion of eligible entities and impacts of health care reform changes

HR 6331 - patent issues associated with anti-biotics S. 3677, HR 4899 - legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Participate in executive branch discussions regarding intellectual property issues arising in foreign countries

HR 6331 - patent issues associated with anti-biotics S. 3677, HR 4899 - legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Participate in executive branch discussions regarding intellectual property issues arising in foreign countries

HR 3590, S 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to healthcare reform legislation and implementation, including the newly-created Independent Payment Advisory Board, evidence-based medicine, and health information technology HR 6331 - issues related to antibiotic development legislation Monitoring and discussing issues under discussion by the President's Deficit Commission, including recommendations regarding the Independent Payment Advisory Board and Medicare Part D rebates (unassigned) Monitoring implementation of existing legislative and regulatory proposals and possible future legislative developments regarding Health Information Technology and Personal Health Records (unassigned) Participate in executive branch discussions regarding pharmaceutical pricing and reimbursement regimes in foreign countries

HR 3590, S 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to healthcare reform legislation and implementation, including the newly-created Independent Payment Advisory Board, evidence-based medicine, and health information technology HR 6331 - issues related to antibiotic development legislation Monitoring and discussing issues under discussion by the President's Deficit Commission, including recommendations regarding the Independent Payment Advisory Board and Medicare Part D rebates (unassigned) Monitoring implementation of existing legislative and regulatory proposals and possible future legislative developments regarding Health Information Technology and Personal Health Records (unassigned) Participate in executive branch discussions regarding pharmaceutical pricing and reimbursement regimes in foreign countries

HR 3590, S 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to pharmaceutical price calculation and reporting HR 3590, S 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicare Part D Coverage Gap Program

HR 3590, S 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to healthcare reform legislation and implementation, including the newly-created Independent Payment Advisory Board, evidence-based medicine, and health information technology HR 6331 - issues related to antibiotic development legislation Monitoring and discussing issues under discussion by the President's Deficit Commission, including recommendations regarding the Independent Payment Advisory Board and Medicare Part D rebates (unassigned) Monitoring implementation of existing legislative and regulatory proposals and possible future legislative developments regarding Health Information Technology and Personal Health Records (unassigned) Participate in executive branch discussions regarding pharmaceutical pricing and reimbursement regimes in foreign countries

HR 3590, S 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to pharmaceutical price calculation and reporting HR 3590, S 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicare Part D Coverage Gap program 340B Drug Pricing program issues (currently unassigned), including program expansion

HR 3590, S 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to pharmaceutical price calculation and reporting HR 3590, S 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicare Part D Coverage Gap Program

HR 3590, S 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to healthcare reform legislation and implementation, including the newly-created Independent Payment Advisory Board, evidence-based medicine, and health information technology

HR 3590, S 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to healthcare reform legislation and implementation, including the newly-created Independent Payment Advisory Board, evidence-based medicine, and health information technology HR 6331 - issues related to antibiotic development legislation Monitoring and discussing issues under discussion by the President's Deficit Commission, including recommendations regarding the Independent Payment Advisory Board and Medicare Part D rebates (unassigned) Monitoring implementation of existing legislative and regulatory proposals and possible future legislative developments regarding Health Information Technology and Personal Health Records (unassigned) Participate in executive branch discussions regarding pharmaceutical pricing and reimbursement regimes in foreign countries

HR. 3590, S 1796 and related bills and amendments - legislative proposals surrounding health care reform including provisions regarding pharmaceutical pricing and proposed revisions to 340B program FDA appropriations issues (currently unassigned)